Literature DB >> 31558385

[What is an efficient health intervention in Spain in 2020?]

José Antonio Sacristán1, Juan Oliva2, Carlos Campillo-Artero3, Jaume Puig-Junoy4, José Luis Pinto-Prades5, Tatiana Dilla6, Carlos Rubio-Terrés7, Vicente Ortún4.   

Abstract

Fifteen years ago, Gaceta Sanitaria published the article entitled "What is an efficient health technology in Spain?" The growing interest in setting the price of new technologies based on the value they provide to health systems and the experience accumulated by the countries in our environment make it opportune to review what constitutes an efficient health intervention in Spain in 2020. Cost-effectiveness analysis continues to be the reference method to maximize social health outcomes with the available resources. The interpretation of its results requires establishing reference values that serve as a guide on what constitutes a reasonable value for the health care system. Efficiency thresholds must be flexible and dynamic, and they need to be updated periodically. Its application should be based on and transparency, and consider other factors that reflect social preferences. Although setting thresholds is down to political decision-makers, in Spain it could be reasonable to use thresholds of 25,000 and 60,000 Euros per QALY. However, currently, in addition to determining exact figures for the threshold, the key question is whether the Spanish National Health System is able and willing to implement a payment model based on value, towards achieving gradual financing decisions and, above all, to improve the predictability, consistency and transparency of the process.
Copyright © 2019 SESPAS. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; Coste-efectividad; Economic evaluation; Efficiency; Eficiencia; Evaluación económica; Financiación; Financing; Health technology; Medicamento; Pharmaceuticals; Precio; Price; Tecnología sanitaria; Threshold; Umbral

Year:  2019        PMID: 31558385     DOI: 10.1016/j.gaceta.2019.06.007

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  10 in total

1.  Real-World Cost-Effectiveness Analysis of Spinal Cord Stimulation vs Conventional Therapy in the Management of Failed Back Surgery Syndrome.

Authors:  Elena Rojo; Concepción Pérez Hernández; Noelia Sánchez Martínez; A César Margarit; Tania Blanco Arias; Manuel Muñoz Martínez; Carlos Crespo; Dolores Ochoa Mazarro
Journal:  J Pain Res       Date:  2021-09-24       Impact factor: 3.133

2.  Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients.

Authors:  Elizabeth Parody-Rua; Alejandro Bustamante; Joan Montaner; Maria Rubio-Valera; David Serrano; Soledad Pérez-Sánchez; Alba Sánchez-Viñas; César Guevara-Cuellar; Antoni Serrano-Blanco
Journal:  Eur J Health Econ       Date:  2022-07-27

3.  Research can be integrated into public health policy-making: global lessons for and from Spanish economic evaluations.

Authors:  Marta Trapero-Bertran; Subhash Pokhrel; Stephen Hanney
Journal:  Health Res Policy Syst       Date:  2022-06-18

4.  Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain.

Authors:  Jesús Ruiz-Aragón; Sergio Márquez-Peláez; Ray Gani; Piedad Alvarez; Richard Guerrero-Luduena
Journal:  Vaccines (Basel)       Date:  2022-01-23

5.  Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.

Authors:  Federico Rojo; Esther Conde; Héctor Torres; Luis Cabezón-Gutiérrez; Dolores Bautista; Inmaculada Ramos; David Carcedo; Natalia Arrabal; J Francisco García; Raquel Galán; Ernest Nadal
Journal:  BMC Cancer       Date:  2022-03-19       Impact factor: 4.430

6.  Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.

Authors:  Mariana Bastos-Oreiro; Ana de Las Heras; María Presa; Miguel A Casado; Carlos Pardo; Victoria Martín-Escudero; Anna Sureda
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

7.  Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.

Authors:  Laura Vallejo-Torres; Borja García-Lorenzo; Laura Catherine Edney; Niek Stadhouders; Ijeoma Edoka; Iván Castilla-Rodríguez; Lidia García-Pérez; Renata Linertová; Cristina Valcárcel-Nazco; Jonathan Karnon
Journal:  Appl Health Econ Health Policy       Date:  2021-12-29       Impact factor: 3.686

8.  An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.

Authors:  Anna Fochesato; Sara Sottile; Andrea Pugliese; Sergio Márquez-Peláez; Hector Toro-Diaz; Ray Gani; Piedad Alvarez; Jesús Ruiz-Aragón
Journal:  Vaccines (Basel)       Date:  2022-08-20

9.  The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.

Authors:  José Ramón Azanza; Santiago Grau; Lourdes Vázquez; Pablo Rebollo; Carmen Peral; Alejandra López-Ibáñez de Aldecoa; Vanessa López-Gómez
Journal:  Mycoses       Date:  2020-10-30       Impact factor: 4.377

10.  Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.

Authors:  Ernest Nadal; Dolores Bautista; Luis Cabezón-Gutiérrez; Ana Laura Ortega; Héctor Torres; David Carcedo; Lucía Ruiz de Alda; J Francisco Garcia; Paula Vieitez; Federico Rojo
Journal:  BMC Cancer       Date:  2021-06-10       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.